View Item 

Show simple item record

Human T Cell Lymphotrophic Virus 1/2 in Solid Organ Transplantation
dc.contributor.authorKaul, D. R.en_US
dc.contributor.authorDavis, J. A.en_US
dc.date.accessioned2013-04-08T20:49:43Z
dc.date.available2014-05-01T14:28:25Zen_US
dc.date.issued2013-03en_US
dc.identifier.citationKaul, D. R.; Davis, J. A. (2013). "Human T Cell Lymphotrophic Virus 1/2 in Solid Organ Transplantation." American Journal of Transplantation 13(s4): 355-360. <http://hdl.handle.net/2027.42/97196>en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97196
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherLeukemiaen_US
dc.subject.otherScreeningen_US
dc.subject.otherHuman T Lymphotrophic Virusen_US
dc.subject.otherDonor‐To‐Host Transmissionen_US
dc.titleHuman T Cell Lymphotrophic Virus 1/2 in Solid Organ Transplantationen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23465028en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97196/1/ajt12127.pdf
dc.identifier.doi10.1111/ajt.12127en_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferenceHuang RC, Fishman JA. Screening of deceased organ donors: No easy answers. Transplantation 2011; 91: 146 – 149.en_US
dc.identifier.citedreferenceLee TH, Chafets DM, Busch MP, Murphy EL. Quantitation of HTLV‐I and II proviral load using real‐time quantitative PCR with SYBR Green chemistry. J Clin Virol 2004; 31: 275 – 282.en_US
dc.identifier.citedreferencePackage Insert: Abbott HTLV‐I/HTLV‐II EIA.en_US
dc.identifier.citedreferenceGout O, Gessain A, Iba‐Zizen M, et al. The effect of zidovudine on chronic myelopathy associated with HTLV‐1. J Neurol 1991; 238: 108 – 109.en_US
dc.identifier.citedreferenceMartin F, Taylor GP. Prospects for the management of human T‐cell lymphotropic virus type 1‐associated myelopathy. AIDS Rev 2011; 13: 161 – 170.en_US
dc.identifier.citedreferenceSheremata WA, Benedict D, Squilacote DC, Sazant A, DeFreitas E. High‐dose zidovudine induction in HTLV‐I‐associated myelopathy: Safety and possible efficacy. Neurology 1993; 43: 2125 – 2129.en_US
dc.identifier.citedreferenceTaylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, et al. Zidovudine plus lamivudine in human T‐lymphotropic virus type‐I‐associated myelopathy: A randomised trial. Retrovirology 2006; 3: 63 – 71.en_US
dc.identifier.citedreferenceTreviño A, Parra P, Bar‐Magen T, Garrido C, de Mendoza C, Soriano V. Antiviral effect of raltegravir on HTLV‐1 carriers. J Antimicrobial Chemother 2012; 67: 218 – 221.en_US
dc.identifier.citedreferenceFood and Drug Administration. 2012; Available at: www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/licensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm090707.htm. Accessed May 15, 2012.en_US
dc.identifier.citedreferenceGrassi MFR, Olavarria VN, Kruschewsky RdA, et al. Human T cell lymphotropic virus type 1 (HTLV‐1) proviral load of HTLV‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol 2011; 83: 1269 – 1274.en_US
dc.identifier.citedreferenceSilva MT, Harab RC, Leite AC, Schor D, Araujo A, Andrada‐Serpa MJ. Human T lymphotropic virus type 1 (HTLV‐1) proviral load in asymptomatic carriers, HTLV‐1‐associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV‐1 infection. Clin Infect Dis 2007; 44: 689 – 692.en_US
dc.identifier.citedreferenceGoncalves DU, Proietti FA, Ribas JG, et al. Epidemiology, treatment, and prevention of human T‐cell leukemia virus type 1‐associated diseases. Clin Microbiol Rev 2010; 23: 577 – 589.en_US
dc.identifier.citedreferenceKataoka R, Takehara N, Iwahara Y, et al. Transmission of HTLV‐I by blood transfusion and its prevention by passive immunization in rabbits. Blood 1990; 76: 1657 – 1661.en_US
dc.identifier.citedreferenceMenna‐Barreto M. HTLV‐II transmission to a health care worker. Am J Infect Control 2006; 34: 158 – 160.en_US
dc.identifier.citedreferenceAmin RM, Jones B, Rubert M, et al. Risk of retroviral infection among retrovirology laboratory and health care workers. American Society for Microbiology 92nd General Meeting, New Orleans, Louisiana, May 26 – 30, 1992. (abstract T‐20).en_US
dc.identifier.citedreferenceElectronic Therapeutic Guidelines. Available at: http://www.tg.org.au/etg_demo/tgc/abg/4651.htm#4703ID_GL. Accessed May 15, 2012.en_US
dc.identifier.citedreferenceSeegulam ME, Ratner L. Integrase inhibitors effective against human T‐cell leukemia virus type 1. Antimicrob Agents Chemother 2011; 55: 2011 – 2017.en_US
dc.identifier.citedreferenceHaynes RA, 2nd, Ware E, Premanandan C, et al. Cyclosporine‐induced immune suppression alters establishment of HTLV‐1 infection in a rabbit model. Blood 2010; 115: 815 – 823.en_US
dc.identifier.citedreferenceBlattner WA, Saxinger C, Riedel D, et al. A study of HTLV‐I and its associated risk factors in Trinidad and Tobago. J Acquir Immune Defic Syndr 1990; 3: 1102 – 1108.en_US
dc.identifier.citedreferenceProietti FA, Carneiro‐Proietti AB, Catalan‐Soares BC, Murphy EL. Global epidemiology of HTLV‐I infection and associated diseases. Oncogene 2005; 24: 6058 – 6068.en_US
dc.identifier.citedreferenceGlynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion‐transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000; 284: 229 – 235.en_US
dc.identifier.citedreferenceClaquin J, Romano P, Noury D, et al. Human T lymphotropic virus 1–2 positive antibodies in potential organ donors in France. Transplant Proc 1996; 28: 189 – 190.en_US
dc.identifier.citedreferenceKaul DR, Taranto S, Alexander C, et al. Donor screening for human T‐cell lymphotrophic virus 1/2: Changing paradigms for changing testing capacity. Am J Transplant 2010; 10: 207 – 213.en_US
dc.identifier.citedreferenceManns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV‐I and risk factors associated with seroconversion. Int J Cancer 1992; 51: 886 – 891.en_US
dc.identifier.citedreferenceMartin‐Davila P, Fortun J, Lopez‐Velez R, et al. Transmission of tropical and geographically restricted infections during solid‐organ transplantation. Clin Microbiol Rev 2008; 21: 60 – 96.en_US
dc.identifier.citedreferenceMurphy E, Roucoux D. The epidemiology and disease outcomes of human T‐lymphotropic virus type II. AIDS Rev 2004; 6: 144 – 154.en_US
dc.identifier.citedreferenceNakamura N, Tamaru S, Ohshima K, Tanaka M, Arakaki Y, Miyauchi T. Prognosis of HTLV‐I‐positive renal transplant recipients. Transplant Proc 2005; 37: 1779 – 1782.en_US
dc.identifier.citedreferenceTanabe K, Kitani R, Takahashi K, et al. Long‐term results in human T‐cell leukemia virus type 1‐positive renal transplant recipients. Transplant Proc 1998; 30: 3168 – 3170.en_US
dc.identifier.citedreferenceShirai H, Suzuki M, Tomita Y, et al. Renal transplantation in patients with human T‐cell lymphotropic virus type 1. Transplant Proc 2012; 44: 83 – 86.en_US
dc.identifier.citedreferenceHoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan. Intl J Cancer 2001; 91: 869 – 875.en_US
dc.identifier.citedreferenceYoshizumi T, Shirabe K, Ikegami T, et al. Impact of human T cell leukemia virus type 1 in living donor liver transplantation. Am J Transplant 2012; 12: 1479 – 1485.en_US
dc.identifier.citedreferenceMarvin MR, Brock GN, Kwarteng K, et al. Increasing utilization of human T‐cell lymphotropic virus (+) donors in liver transplantation: Is it safe? Transplantation 2009; 87: 1180 – 1190.en_US
dc.identifier.citedreferenceShames BD, D'Alessandro AM, Sollinger HW. Human T‐cell lymphotrophic virus infection in organ donors: A need to reassess policy? Am J Transplant 2002; 2: 658 – 663.en_US
dc.identifier.citedreferenceRemesar MC, del Pozo AE, Pittis MG, Mangano AM, Sen L, Briones L. Transmission of HTLV‐I by kidney transplant. Transfusion 2000; 40: 1421 – 1422.en_US
dc.identifier.citedreferenceToro C, Benito R, Aguilera A, et al. Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. J Med Virol 2005; 76: 268 – 270.en_US
dc.identifier.citedreferenceYara S, Fujita J, Date H. Transmission of human T‐lymphotropic virus type I by bilateral living‐donor lobar lung transplantation. J Thorac Cardiovasc Surg 2009; 138: 255 – 256.en_US
dc.identifier.citedreferenceNakamura N, Arakaki Y, Sunagawa H, et al. Influence of immunosuppression in HTLV‐1‐positive renal transplant recipients. Transplant Proc 1998; 30: 1324 – 1326.en_US
dc.identifier.citedreferenceGout O, Baulac M, Gessain A, et al. Rapid development of myelopathy after HTLV‐I infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990; 322: 383 – 388.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajt12127.pdf
Size:
456.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.